Changes in body weight and psychotropic drugs: A systematic synthesis of the literature

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Dent, Robert ^a,c   Blackmore, Angelique ^a   Peterson, Joan ^b   Habib, Rami ^c   Kay, Gary Peter ^c   Gervais, Alan ^a   Taylor, Valerie ^d   Wells, George ^e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ARIPIPRAZOLE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; IMIPRAMINE; ISOCARBOXAZID; MIRTAZAPINE; MOLINDONE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENELZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRANYLCYPROMINE; TRIMIPRAMINE; UNINDEXED DRUG; ZIPRASIDONE;

CLINICAL ASSESSMENT TOOL; DISEASE ASSOCIATION; DRUG SAFETY; HUMAN; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT CHANGE; WEIGHT GAIN;

BODY WEIGHT; HUMANS; PSYCHOTROPIC DRUGS; WEIGHT GAIN;

EID: 84862500829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036889     Document Type: Review

References (132)

1. Bramlage P, Wittchen HU, Pittrow D, Kirch W, Krause P, et al. (2004) Recognition and management of overweight and obesity in primary care in Germany. Int J Obes Relat Metab Disord 28: 1299-1308.
2. Mackin P, Bishop DR, Watkinson HM, (2007) A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 7: 28.
3. Suppes T, McElroy SL, Hirschfeld R, (2007) Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. Psychopharmacol Bull 40: 22-37; quiz 38-40.
4. Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM, (2005) Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 79: 281-288.
5. Feeney L, Mooney M, (2005) Atypical antipsychotic monitoring in the Kilkenny Mental Health Services. Irish Journal of Psychological Medicine 22: 101-102.
6. Boilson M, Hamilton RJ, (2003) A survey of monitoring of weight and blood glucose in in-patients. Psychiatric Bulletin 27: 424-426.
7. Nguyen D, Brakoulias V, Boyce P, (2009) An evaluation of monitoring practices in patients on second generation antipsychotics. Australas Psychiatry 17: 295-299.
8. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, et al. (2009) Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32: 1037-1042.
9. Cash TF, Brown MA, (2000) Attitudes about antidepressants: influence of information about weight-related side effects. Percept Mot Skills 90: 453-456.
10. Ashton AK, Jamerson BD, Weinstein WL, Wagoner C, (2005) Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Current Therapeutic Research- Clinical and Experimental 66: 96-106.
11. Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA, (2007) Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol 27: 451-458.
12. Shelton RC, (2007) Issues related to adherence in the treatment of depression. Primary Psychiatry 14: 42-46.
13. Anderson IM, Nutt DJ, Deakin JF, (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 14: 3-20.
14. Masand PS, (2003) Tolerability and adherence issues in antidepressant therapy. Clin Ther 25: 2289-2304.
15. Perkins DO, (2002) Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63: 1121-1128.
16. Sussman N, (2003) The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 23: S21-26.
17. Allison DB, Mackell JA, McDonnell DD, (2003) The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 54: 565-567.
18. Weiden PJ, Mackell JA, McDonnell DD, (2004) Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66: 51-57.
19. Tham M, Jones S, Chamberlain J, Castle D, (2007) The impact of psychotropic weight gain on people with psychosis-patient perspectives and attitudes. Journal of Mental Health 16: 771-779.
20. Hamer S, Haddad PM, (2007) Adverse effects of antipsychotics as outcome measures. Br J Psychiatry pp. s64-70.
21. Haddad PM, Sharma SG, (2007) Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21: 911-936.
22. Henderson DC, (2007) Weight gain with atypical antipsychotics: evidence and insights. J Clin Psychiatry 68: 18-26.
23. Gitlin MJ, Cochran SD, Jamison KR, (1989) Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 50: 127-131.
24. Anderson T, Goldberg J, Harrow M, (2004) A review of medication side effects and treatment adherence in bipolar disorder. Primary Psychiatry 11: 48-54.
25. Lindenmayer JP, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, et al. (2009) Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 70: 990-996.
26. Bellack AS, Bowden CL, Bowie CR, Byerly MJ, Carpenter WT, (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. Journal of Clinical Psychiatry 70: 1-48.
27. Thieda P, Beard S, Richter A, Kane J, (2003) An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 54: 508-516.
28. Sun SX, Liu GG, Christensen DB, Fu AZ, (2007) Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 23: 2305-2312.
29. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
30. Beasley CM Jr, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, et al. (2007) All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol 27: 252-258.
31. Sernyak MJ, Leslie DL, Alarcon RD, Losoncrzy MF, Rosenheck R, (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159: 561-566.
32. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, et al. (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 157: 975-981.
33. Leslie DL, Rosenheck RA, (2004) Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 161: 1709-1711.
34. Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O, (2002) Glucose intolerance with atypical antipsychotics. Drug Saf 25: 1107-1116.
35. Kurzthaler I, Fleischhacker WW, (2001) The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 62: 32-37.
36. Allison DB, Casey DE, (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62: 22-31.
37. Aronne LJ, Segal KR, (2003) Weight gain in the treatment of mood disorders. J Clin Psychiatry 64: 22-29.
38. Newcomer JW, (2004) Metabolic risk during antipsychotic treatment. Clin Ther 26: 1936-1946.
39. Bergman RN, Ader M, (2005) Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 66: 504-514.
40. Nasrallah HA, Newcomer JW, (2004) Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 24: S7-14.
41. McIntyre RS, McCann SM, Kennedy SH, (2001) Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 46: 273-281.
42. Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, et al. (2005) Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 162: 1535-1538.
43. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, et al. (2001) Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101: 277-288.
44. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, et al. (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334-1349.
45. American Diabetes Association APA, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity, (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596-601.
46. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, et al. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 117: S26-43.
47. Schatzberg AF, (2007) Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 68: 26-34.
48. Malone M, (2005) Medications associated with weight gain. Ann Pharmacother 39: 2046-2055.
49. Perucca E, Meador KJ, (2005) Adverse effects of antiepileptic drugs. Acta Neurol Scand pp. 30-35.
50. Sachs GS, Guille C, (1999) Weight gain associated with use of psychotropic medications. J Clin Psychiatry 60: 16-19.
51. Weiden PJ, (2007) Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry 68: 34-39.
52. Nasrallah HA, (2007) The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry 68: 5-11.
53. Nasrallah HA, (2003) Factors in antipsychotic drug selection: tolerability considerations. CNS Spectr 8: 23-25.
54. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, et al. (2009) Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 107: 22-29.
55. Serretti A, Mandelli L, (2010) Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 71: 1259-1272.
56. Citrome L, (2007) The effectiveness criterion: balancing efficacy against the risks of weight gain. J Clin Psychiatry 68: 12-17.
57. El-Khayat R, Baldwin DS, (1998) Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder. J Psychopharmacol 12: 323-329.
58. Gao K, Muzina D, Gajwani P, Calabrese JR, (2006) Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 67: 1327-1340.
59. Jeste DV, Dolder CR, (2004) Treatment of non-schizophrenic disorders: focus on atypical antipsychotics. J Psychiatr Res 38: 73-103.
60. Garland EJ, Remick RA, Zis AP, (1988) Weight gain with antidepressants and lithium. J Clin Psychopharmacol 8: 323-330.
61. Cantu TG, Korek JS, (1988) Monoamine oxidase inhibitors and weight gain. Drug Intell Clin Pharm 22: 755-759.
62. Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, Hetrick S, Rodriguez-Sanchez JM, et al. (2008) Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 22: 547-562.
63. Leucht S, Corves C, Arbter D, Engel RR, Li C, et al. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31-41.
64. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, et al. (2010) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev CD006625.
65. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696.
66. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS, (2005) Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143: 415-426.
67. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, et al. (2008) Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 31: 851-865.
68. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, et al. (2008) Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 149: 734-750.
69. Montgomery SA, Reimitz PE, Zivkov M, (1998) Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 13: 63-73.
70. Feighner J, Hendrickson G, Miller L, Stern W, (1986) Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 6: 27-32.
71. Harris B, Young J, Hughes B, (1986) Comparative effects of seven antidepressant regimes on appetite, weight and carbohydrate preference. Br J Psychiatry 148: 590-592.
72. Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato LM, et al. (2004) Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24: 118-125.
73. Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM, (2004) A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24: 49-55.
74. Perry R, Cassagnol M, (2009) Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther 31 Pt 1: 1374-1404.
75. Taylor DM, McAskill R, (2000) Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand 101: 416-432.
76. Johnsen E, Jorgensen HA, (2008) Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 8: 31.
77. Melvin CL, Carey TS, Goodman F, Oldham JM, Williams JW Jr, et al. (2008) Effectiveness of antiepileptic drugs for the treatment of bipolar disorder: findings from a systematic review. J Psychiatr Pract 14: 9-14.
78. Bowden CL, Mosolov S, Hranov L, Chen E, Habil H, et al. (2010) Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol 25: 60-67.
79. Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, et al. (2006) Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 163: 1199-1201.
80. Leslie WS, Hankey CR, Lean ME, (2007) Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 100: 395-404.
81. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD, (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62: 92-100.
82. Tran PV, Tollefson GD, Sanger TM, Lu Y, Berg PH, et al. (1999) Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. Br J Psychiatry 174: 15-22.
83. Benazzi F, (1998) Weight gain in depression remitted with antidepressants: pharmacological or recovery effect? Psychother Psychosom 67: 271-274.
84. Gentile S, (2009) Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 10: 527-542.
85. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, et al. (2000) Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 148: 83-89.
86. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, et al. (2004) Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 19: 1123-1130.
87. Seeman MV, (2009) Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull 35: 937-948.
88. Lencz T, Malhotra AK, (2009) Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci 11: 405-415.
89. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, et al. (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 43: 620-626.
90. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, et al. (2005) Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 187: 537-543.
91. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M, (2004) Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 65: 1084-1089.
92. Ahmer S, Arya P, Anderson D, Faruqui R, (2005) Conflict of interest in psychiatry. Psychiatric Bulletin 29: 302-304.
93. Sismondo S, (2008) Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 29: 109-113.
94. Barbui C, Cipriani A, Brambilla P, Hotopf M, (2004) "Wish bias" in antidepressant drug trials? J Clin Psychopharmacol 24: 126-130.
95. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, et al. (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163: 185-194.
96. Gartlehner G, Morgan L, Thieda P, Fleg A, (2010) The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review. J Clin Epidemiol 63: 117-125.
97. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, et al. (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 7: 10.
98. SIGN 50 website. Available:http://www.sign.ac.uk/guidelines/fulltext/50/annexc.html. Accessed 2011 Apr 24.
99. Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, et al. (2004) Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 173-180.
100. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. (2010) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev CD006654.
101. Karagianis J, Hoffmann VP, Arranz B, Treuer T, Maguire GA, et al. (2008) Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Hum Psychopharmacol 23: 275-281.
102. Canas F, Moller HJ, (2010) Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. Expert Opin Drug Saf 9: 683-697.
103. Fenton M, Rathbone J, Reilly J, Sultana A, (2007) Thioridazine for schizophrenia. Cochrane Database Syst Rev CD001944.
104. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, et al. (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28: 995-1003.
105. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, et al. (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164: 1050-1060.
106. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. (2010) Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev CD006624.
107. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, et al. (2009) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev CD006569.
108. Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, et al. (2009) Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin Neurosci 63: 73-81.
109. Bechelli LPC, Iecco MC, Acioli A, Pontes MC, (1985) A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public out-patient clinic. Current Therapeutic Research- Clinical and Experimental 37: 662-671.
110. Wistedt B, Persson T, Hellbom E, (1984) A clinical double-blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research- Clinical and Experimental 35: 804-814.
111. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, et al. (2009) Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev CD006627.
112. Bagnall A, Fenton M, Kleijnen J, Lewis R, (2007) Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev CD002083.
113. Sivaraman P, Rattehalli RD, Jayaram MB, (2010) Levomepromazine for schizophrenia. Cochrane Database Syst Rev CD007779.
114. Marques LO, Lima MS, Soares BG, (2004) Trifluoperazine for schizophrenia. Cochrane Database Syst Rev CD003545.
115. Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, et al. (2007) Loxapine for schizophrenia. Cochrane Database Syst Rev CD001943.
116. Johnson DA, Breen M, (1979) Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatr Scand 59: 525-528.
117. Kumar A, Strech D, (2009) Zuclopenthixol dihydrochloride for schizophrenia. Schizophr Bull 35: 855-856.
118. Chwieduk CM, Keating GM, (2010) Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 70: 1295-1317.
119. Citrome L, (2010) Paliperidone palmitate- review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 64: 216-239.
120. Okugawa G, Kato M, Wakeno M, Koh J, Morikawa M, et al. (2009) Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci 63: 322-328.
121. Marino J, Caballero J, (2010) Iloperidone for the treatment of schizophrenia. Ann Pharmacother 44: 863-870.
122. Hale KS, (2010) Iloperidone- A second-generation antipsychotic for the treatment of acute schizophrenia. The Journal of Pharmacy Technology 26: 193-202.
123. Bisol LW, Brunstein MG, Ottoni GL, Ramos FL, Borba DL, et al. (2008) Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. J Clin Psychiatry 69: 1572-1579.
124. Citrome L, (2009) Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 63: 1762-1784.
125. Smith MC, Centorrino F, Welge JA, Collins MA, (2004) Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav 5: 746-751.
126. Ketter TA, Kalali AH, Weisler RH, (2004) A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 65: 668-673.
127. Reinstein MJ, Sonnenberg JG, Hedberg TG, Jones LE, Reyngold P, (2003) Oxcarbazepine versus Divalproex Sodium for the Continuing Treatment of Mania. Clin Drug Investig 23: 671-677.
128. Stoffers J, Vollm BA, Rucker G, Timmer A, Huband N, et al. (2010) Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev CD005653.
129. Oswald I, Adam K, (1980) Benzodiazepines cause small loss of body weight. Br Med J 281: 1039-1040.
130. Bjertnaes A, Block JM, Hafstad PE, Holte M, Ottemo I, et al. (1982) A multicentre placebo-controlled trial comparing the efficacy of mianserin and chlordiazepoxide in general practice patients with primary anxiety. Acta Psychiatr Scand 66: 199-207.
131. Smits JA, Rosenfield D, Mather AA, Tart CD, Henriksen C, et al. (2010) Psychotropic medication use mediates the relationship between mood and anxiety disorders and obesity: findings from a nationally representative sample. J Psychiatr Res 44: 1010-1016.
132. Yuanguang CC, Xiaogang C, Chuanyue W, (1998) A randomized controlled study of buspirone and valium in the treatment of general anxiety disorder. Chinese Journal of Psychiatry 31: 43-46.